Flupentixol

證據等級: L5

預測適應症: 9 個

Flupentixol: From Psychosis to Retinal Dystrophy with Extraocular Anomalies

One-Sentence Summary

Flupentixol is a thioxanthene-class typical antipsychotic, used internationally for schizophrenia, psychosis, and depression, and is not registered in the Philippines. The TxGNN model predicts it may be effective for Retinal Dystrophy with or without Extraocular Anomalies with a prediction score of 99.99%; however, no clinical trials exist for this indication, all 15 retrieved publications are general ophthalmic reviews unrelated to Flupentixol treatment, and evidence analysis strongly suggests this is a direction-reversed false positive that warrants no further development.

Quick Overview

Item	Content
Original Indication	Psychosis / Schizophrenia (international use; not registered in Philippines)
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.99%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological information, Flupentixol is a thioxanthene-class typical antipsychotic that primarily antagonizes dopamine D1/D2 receptors and serotonin receptors. It is used internationally for schizophrenia, psychosis, and depressive disorders. Its original indication bears no pathophysiological overlap with inherited retinal dystrophies, which are caused by mutations in genes governing photoreceptor structure and function (e.g., RPGR, RPGRIP1).

⚠️ Direction Reversal Warning — This prediction is highly likely to be a false positive. Flupentixol is a known cause of drug-induced pigmentary retinopathy as a long-term adverse effect. The mechanism involves D2 receptor blockade in the retinal pigment epithelium (RPE) combined with melanin binding and toxic pigment deposition, resulting in progressive retinal damage rather than therapeutic benefit. The TxGNN knowledge graph most likely captured the “Flupentixol ↔ retinal pigment epithelium ↔ retinal dystrophy” association from adverse event data, and incorrectly reinterpreted this toxicity edge as a therapeutic signal.

This concern is compounded by the complete absence of any disease-specific literature: all 15 retrieved publications are general ophthalmic reviews covering topics such as orbital infections, congenital ptosis, lens anomalies, and extraocular muscle disorders. Not a single study examines Flupentixol as a treatment — or even an investigational candidate — for retinal dystrophy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

⚠️ None of the following publications examine Flupentixol as a treatment for retinal dystrophy. They are general ophthalmic references retrieved via co-occurrence search and are listed for transparency only. Their relevance to this repurposing hypothesis is classified as indirect at best.

PMID	Year	Type	Journal	Key Findings
38321238	2024	Review	Pediatric Radiology	Differential diagnosis and key imaging features of pediatric ocular pathologies including congenital/developmental lesions
38249493	2023	Review	Taiwan J Ophthalmology	Congenital anomalies of lens shape; association with anterior segment dysgenesis and hyperplastic vitreous
33806565	2021	Research Article	Int J Mol Sciences	Optic nerve head and retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM) caused by KIF21A/TUBB3 mutations
33447730	2020	Review	Ther Adv Ophthalmology	Eye involvement in inherited metabolic disorders; cornea, lens, retina, and extraocular muscle abnormalities
30747268	2019	Review	Neuroradiology	Neuroradiological and clinical features in ophthalmoplegia for differential diagnosis and treatment guidance
30196776	2018	Review	J Binocular Vision Ocular Motility	Congenital cranial dysinnervation disorders (CCDDs) and their various forms of ophthalmoplegia
24932988	2014	Research Article	Am J Ophthalmology	Pathogenesis and treatment of maculopathy associated with cavitary optic disc anomalies
24413161	2014	Case Report	J Neuro-Ophthalmology	Isolated case of congenital trochlear-oculomotor synkinesis in a 6-year-old; proposed pathophysiology of CCDDs
20127583	2010	Review/Clinical Pearl	Seminars in Neurology	Systematic history and examination approach to patients presenting with diplopia
19064847	2008	Case Series	Arch Ophthalmology	Clinical features, management, and outcomes in patients with orbital arteriovenous malformations

Philippines Market Information

Flupentixol has no market authorization in the Philippines. No product registrations, approved indications, or dosage form data are available.

Safety Considerations

Please refer to the package insert for complete safety information.

As a thioxanthene-class typical antipsychotic, Flupentixol carries well-established class-level risks that are directly relevant to this repurposing assessment:

Drug-induced pigmentary retinopathy: A documented long-term adverse effect of Flupentixol and related phenothiazine/thioxanthene drugs, caused by toxic pigment deposition in the RPE. This is the probable source of the KG prediction and represents an active safety concern, not a therapeutic signal.
Extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome are additional class-level concerns.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is a likely direction-reversed false positive — Flupentixol’s documented association with retinal pathology is as a causative toxin (drug-induced pigmentary retinopathy), not as a therapeutic agent. No clinical trials, no disease-specific preclinical studies, and no mechanistic rationale support its use in retinal dystrophy. All 9 predicted indications across this Evidence Pack similarly returned zero clinical trials and zero disease-specific literature, suggesting a systemic model limitation for this drug rather than isolated noise.

To proceed, the following would be needed:

MOA data retrieval from DrugBank to formally characterize Flupentixol’s receptor pharmacology and rule out any secondary beneficial pathway
Adverse event / pharmacovigilance review to confirm the retinal toxicity signal and document it as a contraindication for this repurposing direction
TxGNN knowledge graph audit to determine whether adverse event edges are being misclassified as therapeutic edges — particularly for drugs in the phenothiazine/thioxanthene class
Philippines FDA package insert (if available from import registrations in neighboring markets) for full safety and contraindication profile
If further exploration is desired despite this assessment, a formal preclinical study in a validated retinal dystrophy animal model with full safety monitoring would be the minimum required threshold before any clinical consideration

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.